Please assess the completion status of the following clinical trial:

Trial Title: Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, incurable esophageal or gastric carcinoma (carcinoma = adenocarcinoma or squamous cell carcinoma)~* Measurable disease \> 1cm (longest diameter) by spiral CT scan or \> 2cm by other radiographic technique.~* Lesions must be measurable in at least one dimension.~* Bone lesions, ascites and effusions are not measurable.~* Irradiated lesions are not measurable yet lesions arising in previously irradiated fields are measurable.~* Age 18+ years.~* ECOG performance status 0 or 1.~* Life expectancy greater than 12 weeks.~* Adequate bone marrow function.~* Adequate renal function: creatinine equal to or less than 1.5 mg/dl.~* SGOT less than 2.5 x institutional upper limit of normal if alkaline phosphatase is within institutional upper limit of normal.~* Alkaline phosphatase less than 4.0 x upper limit of normal if SGOT is within institutional upper limit of normal.~* For patients with both SGOT and alkaline phosphatase elevations, SGOT must be less than 1.5 x institutional upper limit of normal and alkaline phosphatase must be less 2.5 x institutional upper limit of normal. For patients with liver metastases, however, SGOT may be \< 3.0 x institutional upper limit of normal and alkaline phosphatase may be \< 5.0 x institutional upper limit of normal as long as the total bilirubin is within the institutional upper limit of normal.~Exclusion Criteria:~* No prior chemotherapy (except as part of pre- or post-operative therapy, completed \> 1 year prior to start date of this protocol).~* Patients who have received prior pelvic radiation therapy are ineligible. Other prior radiation therapy, however, is permitted, provided at least 4 weeks have elapsed since completion of this therapy and the initiation of this protocol.~* No myocardial infarction in the past six months.~* No major surgery in the past three weeks.~* No uncontrolled serious medical or psychiatric illness.~* No uncontrolled diarrhea.~* Patients with a peripheral neuropathy \> grade 1 will be excluded.~* Women of childbearing potential must have a negative pregnancy test. Men and women of childbearing potential must use adequate contraception.~* No clinically apparent central nervous system metastases or carcinomatous meningitis.~* No other active malignancy other than non-melanoma skin cancer or in-situ cervical carcinoma. A resected cancer (other than in-situ carcinoma) must have demonstrated no evidence of recurrence for at least 3 years.~* Patients with history of severe hypersensitivity to irinotecan, cisplatin, taxotere or drugs formulated with polysorbate 80 must be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).